<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.moneycontrol.com/news/business/laurus-labs-gets-3-observations-from-usfda-for-visakhapatnam-facility-4663031.html"/>
    <meta property="og:site_name" content="Moneycontrol"/>
    <meta property="article:published_time" content="2019-11-21T00:00:00+00:00"/>
    <meta property="og:title" content="Laurus Labs gets 3 observations from USFDA for Visakhapatnam facility"/>
    <meta property="og:description" content="The inspection was completed with three observations, 'which are procedural in nature'."/>
  </head>
  <body>
    <article>
      <h1>Laurus Labs gets 3 observations from USFDA for Visakhapatnam facility</h1>
      <h2>The inspection was completed with three observations, 'which are procedural in nature'.</h2>
      <address><time datetime="2019-11-21T00:00:00+00:00">21 Nov 2019</time> by <a rel="author">PTI</a></address>
      <p>Drug firm <a href="http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/lauruslabs/LL05">Laurus Labs</a> on November 21 said US health regulator has made three observations after completing inspection of its Visakhapatnam facility in Andhra Pradesh.</p>
      <p>The company has completed the pre approval inspection (PAI) for an active pharmaceutical ingredient (API) manufactured at its Units 1&amp;3, located at Visakhapatnam by the United States Food and Drug Administration, Laurus Labs said in a filing to the BSE.</p>
      <p>The inspection was completed with three observations, 'which are procedural in nature'. No data integrity issues were observed in the inspection, it added.</p>
      <p>The company, however, did not provide any details about the observations.</p>
      <p>The inspection was carried out from November 18 – 21, 2019, it added.</p>
      <p>Shares of Laurus Labs closed at Rs 332.15 per scrip on the BSE, down 2.11 per cent from its previous close.</p>
    </article>
  </body>
</html>